西格列汀联合二甲双胍治疗2型糖尿病的临床效果及安全性分析
张军
（新疆吉木萨尔县医院，新疆 昌吉回族自治州，831700）
浏览次数：96次 下载次数：345次
摘要：
目的 观察分析西格列汀联合二甲双胍治疗2型糖尿病的临床效果及安全性。方法 选取2015年6月至2016年6月在我院治疗的2型糖尿病患者68例，将其随机分为对照组和观察组，各34例。对照组患者采用西格列汀治疗，观察组患者采用西格列汀联合二甲双胍治疗，对比两组患者的空腹血糖（FBG）、空腹胰岛素（FINS）、体重指数（BMI）、糖化血红蛋白（HbA1c）、三酰甘油（TG）、胆固醇（TCH）、低密度脂蛋白（LDL-C）及不良反应发生率。结果 治疗后，观察组2型糖尿病患者的 FBG、FINS、BMI、HbA1c、TG、TCH、LDL-C 各指标均优于对照组（P<0.05）；观察组的不良反应发生率为8.82%，低于对照组的29.41%（P<0.05）。结论 西格列汀联合二甲双胍治疗2型糖尿病的临床效果可观，安全性高。
关键词：西格列汀；2 型糖尿病；二甲双胍
中图分类号：R587.1文献标志码：A文章编号：2096-1413(2017)06-0064-02
Clinical efficacy and safety of combination therapy with sitagliptin and metformin
on patients with type 2 diabetes mellitus
ZHANG Jun
(Jimsar People's Hospital, Changji Hui Aotonomous Prefecture 831700, China)
ABSTRACT: Objective To observe the clinical efficacy and safety of sitagliptin combined with metformin in the treatment of type 2 diabetes mellitus. Methods Sixty-eight patients with type 2 diabetes mellitus treated in our hospital from June 2015 to June 2016 were selected as the research objects. All the patients were randomly devided into observation group and control group, with 34 cases in each group. The patients in the control group was treated with sitagliptin, while the patients in the observation group was treated with sitagliptin combined with metformin. The fasting blood glucose (FBG), fasting insulin (FINS), body mass index (BMI), glycosylated hemoglobin (HbA1c), triglycerides (TG), cholesterol (TCH), low density lipoprotein (LDL-C) and the incidence of adverse were compared between the two groups. Results After treatment the FBG, FINS, BMI, HbA1c, TG, TCH and LDL-C of the observation group were better than those of the control group (P<0.05). The complication incidence rate of the observation group was 8.82%, which was lower than 29.41% of the control group (P <0.05). Conclusion Sitagliptin combined with metformin in the treatment of diabetes mellitus type 2 has a remarkable curative effect and high safety for the patients.
KEYWORDS: sitagliptin; diabetes mellitus type 2; metformin
参考文献：
[1] 徐艳丽.西格列汀联合二甲双胍治疗2型糖尿病的疗效及安全性评价[J].临床医药文献杂志:电子版,2016,3(5):970-971.
[2] 刘福平,张星光,陈彬.二甲双胍联合西格列汀或格列美脲对2型糖尿病血糖波动和氧化应激的影响[J].中国现代医学杂志,2015,25(33):71-74.
[3] 段俊婷,彭定琼,董斌,等.西格列汀联合二甲双胍对2型糖尿病患者血糖水平及心血管事件发生率的影响[J].实用临床医药杂志,2016,20(5):18-21.
[4] 徐玉凤,梁勇前,李颖.吡格列酮、西格列汀与二甲双胍联合治疗血糖控制不佳的2型糖尿病肥胖患者的疗效观察[J].中国当代医药,2016,23(17):38-40.
[5] 李秀梅,杨秀红,董陆玲.西格列汀治疗二甲双胍不耐受的新诊断2型糖尿病临床观察[J].河北医药,2016,38(8):1189-1192.
[6] 姚璐,张薇,武云涛,等.磷酸西格列汀联合不同剂量二甲双胍治疗2型糖尿病的临床疗效观察[J].中国循证心血管医学杂志,2015,7(6):807-808.
[7] 韩秀平,孙涛,贺钰梅,等.磷酸西格列汀联合二甲双胍治疗初发2型糖尿病的临床效果[J].中国医药导报,2016,13(12):165-168.
[8] 周迪军,孙文利,丁蓉.西格列汀联合二甲双胍治疗2型糖尿病的临床效果[J].中国医药导报,2014,11(15):84-86.
[9] 段丽君,张扬,江霞.西格列汀联合二甲双胍治疗初诊2型糖尿病的效果观察[J].中国综合临床,2013,29(4):379-382.